Congestive heart failure chronic pharmacotherapy

Resident Survival Guide

Congestive Heart Failure Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology Systolic Dysfunction Diastolic Dysfunction HFpEF HFrEF
Causes
Differentiating Congestive heart failure from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Clinical Assessment
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Cardiac MRI
Echocardiography
Exercise Stress Test
Myocardial Viability Studies
Cardiac Catheterization
Other Imaging Studies
Other Diagnostic Studies
Treatment
Invasive Hemodynamic Monitoring
Medical Therapy:
Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy in HFpEF
Chronic Pharmacotherapy in HFrEF Diuretics ACE Inhibitors Angiotensin receptor blockers Aldosterone Antagonists Beta Blockers Ca Channel Blockers Nitrates Hydralazine Positive Inotropics Anticoagulants Angiotensin Receptor-Neprilysin Inhibitor Antiarrhythmic Drugs Nutritional Supplements Hormonal Therapies Drugs to Avoid Drug Interactions Treatment of underlying causes Associated conditions
Exercise Training
Surgical Therapy: Biventricular Pacing or Cardiac Resynchronization Therapy (CRT) Implantation of Intracardiac Defibrillator Ultrafiltration Cardiac Surgery Left Ventricular Assist Devices (LVADs) Cardiac Transplantation
ACC/AHA Guideline Recommendations Initial and Serial Evaluation of the HF Patient Hospitalized Patient Patients With a Prior MI Sudden Cardiac Death Prevention Surgical/Percutaneous/Transcather Interventional Treatments of HF Patients at high risk for developing heart failure (Stage A) Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B) Patients with current or prior symptoms of heart failure (Stage C) Patients with refractory end-stage heart failure (Stage D) Coordinating Care for Patients With Chronic HF Quality Metrics/Performance Measures
Implementation of Practice Guidelines
Congestive heart failure end-of-life considerations
Specific Groups: Special Populations Patients who have concomitant disorders Obstructive Sleep Apnea in the Patient with CHF NSTEMI with Heart Failure and Cardiogenic Shock
Congestive heart failure chronic pharmacotherapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Congestive heart failure chronic pharmacotherapy
CDC on Congestive heart failure chronic pharmacotherapy
Congestive heart failure chronic pharmacotherapy in the news
Blogs on Congestive heart failure chronic pharmacotherapy
Directions to Hospitals Treating Congestive heart failure chronic pharmacotherapy
Risk calculators and risk factors for Congestive heart failure chronic pharmacotherapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

There are several goals in the chronic management of systolic heart failure. The management of diastolic heart failure is discussed elsewhere. One goal of therapy is to improve the patient's symptoms, exercise tolerance and quality of life. Diuretics, along with regular assessment of the patient's weight, minimizes fluid accumulation and the accompanying symptoms of dyspnea and orthopnea. Another goal is to reduce hospitalization and mortality. To achieve the second goal, patients with chronic heart failure should be administered an ACE inhibitor (or ARB if they are ACE intolerant) and a beta blocker. If the patient remains symptomatic, additional therapy may include an aldosterone antagonist.

Drugs recommended in all patients with heart failure with reduced ejection fraction

Medications indicated in patients with New York Heart Association (NYHA class II–IV) heart failure with reduced ejection fraction (LVEF <_40%)

Recommendations for screening sleep apnea in patients with bradycardia or conduction disorder

(Class I, Level of Evidence A):

❑ ACE-I is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death ❑ Beta-blocker is recommended for patients with stable HFrEF to reduce the risk of HF hospitalization and death ❑ MRA (Mineralocorticoid receptor antagonist) is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death ❑ Dapagliflozin or empagliflozin are recommended for patients with HFrEF to reduce the risk of HF hospitalization and death

(Class I, Level of Evidence B):

❑ Sacubitril/valsartan is recommended as a replacement for an ACE-I in patients with HFrEF to reduce the risk of HF hospitalization and death

The above table adopted from 2021 ESC Guideline

Angiotensin-converting enzyme inhibitors

• ACE-Is are the first class of drugs that reduce mortality and morbidity in patients with HFrEF and improve symptoms.
• ACEI should be Uptitrated to the maximum tolerated recommended dose.

Beta-blockers

• Beta-blockers can reduce mortality and morbidity in patients with HFrEF, in addition to treatment with an ACE-I and diuretic and also improve symptoms.
• In symptomatic heart failure, ACE-I and beta-blockers can be used in combination.
• Initiation of a beta-blocker before an ACE-I and vice versa are not recommended.
• Beta-blockers should be initiated in clinically stable, euvolaemic, patients at a low dose and gradually titrated to the maximum tolerated dose.
• After stability of hemodynamic in patients admitted with acute heart failure, beta-blockers should be cautiously initiated in hospital
• Use of betablocker in patients with HFrEF with AF was not associated with reduction in mortality or hospital admission.

MRA or Mineralocorticoid receptor antagonists

• In all patients with HFrEF, MRAs (spironolactone or eplerenone) are recommended, in addition to an ACE-I and a beta-blocker, to reduce mortality and the risk of heart failure hospitalization.
• MRAs improve symptoms.
• MRAs block receptors that bind aldosterone and also other steroid hormones (corticosteroid and androgen) receptors.
• Eplerenone is more specific for aldosterone blockade and, therefore, causes less gynaecomastia.
• In patients with impaired renal function and in those with serum potassium concentrations >5.0 mmol/L, MRA should be used with causion.

Angiotensin receptor-neprilysin inhibitor

• In the PARADIGM-HF trial, sacubitril/valsartan, an ARNI, was superior to enalapril in reducing hospitalizations for worsening HF, cardiovascular mortality, and all-cause mortality in patients with ambulatory HFrEF with LVEF <_40% (changed to <_35% during the study).
• Patients with elevated plasma NP concentrations, an eGFR >_30 mL/min/1.73 m2 and were able to tolerate enalapril and then sacubitril/valsartan.
• Use of sacubitril/valsartan was associated with improvement in symptoms and quality of life a reduction in the incidence of diabetes requiring insulin treatment,

and a reduction in the decline in eGFR as well as a reduced rate of hyperkalemia.

• In addition, the need for loop diuretic reduced while using of sacubitril/valsartan.
• Common side effect of sacubitril/valsartan is symptomatic hypotension as compared to enalapril, but despite developing hypotension, these patients also gained clinical benefits from sacubitril/valsartan therapy.
• The recommendation is that an ACE-I or ARB is replaced by sacubitril/valsartan in ambulatory patients with HFrEF, who remain symptomatic despite optimal treatment.
• Two studies have shown the use of ARNI in hospitalized patients with adequate blood pressure (BP), and an eGFR >_30 mL/min/1.73 m2, without previously treated with ACE-I, was associated with reduced subsequent cardiovascular death or HF hospitalizations.

Sodium-glucose co-transporter 2 inhibitors

• The result of DAPA-HF trial showed the long-term effects of dapagliflozin (SGLT2 inhibitor) compared to placebo in addition to optimal medical therapy (OMT), on morbidity and mortality in patients with NYHA class II-IV, and had an LVEF <_40%.
• Elevated plasma NT-proBNP and an eGFR >_30 mL/min/1.73 m2 were needed to initiation of therapy.
• Benefits of dapagliflozin in heart failure including:

• Reduction in worsening HF (hospitalization)
• Reduction in cardiovascular death.
• Reduction in all-cause mortality
• Alleviated HF symptomS
• Improvement of physical function and quality of life in patients with symptomatic HFrEF

• Benefits were seen early after the initiation of dapagliflozin.
• Survival benefits were seen in patients with HFrEF with and without diabetes.
• EMPEROR-Reduced trial investigated that empagliflozin reduced the combined primary endpoint of CV death or HF hospitalization by 25% in patients with NYHA class II-IV symptoms, and an LVEF <_40% despiteOMT and eGFR >20 mL/min/1.73 m2.
• Reduction in the decline in eGFR and improvement in quality of life among patients receiving empagliflozin were also found.
• Dapagliflozin or empagliflozin are recommended, in addition to OMT with an ACE-I/ARNI, a beta-blocker and an MRA, for patients with HFrEF regardless of diabetes status.
• The need for diuretic may be reduced due to The diuretic/natriuretic properties of SGLT2 inhibitors and reducing congestion.
• The combined SGLT-1 and SGLT-2 inhibitors, sotagliflozin, has also been investigated in patients with diabetes who were hospitalized with HF.
• Side effects of SGLT2 inhibitors including:

• Increased risk of recurrent genital fungal infections

• A small reversible reduction in eGFR following initiation

Other medications in HFrEF in patients with NYHA 2-4

Recommendations for heart failure with reduced ejection fraction and NYHA 2-4

Loop diuretics (Class I, Level of Evidence C):

❑ Loop diuretics are recommended in patients with HFrEF with signs and/or symptoms of congestion to improve HF symptoms, exercise capacity, and reduce HF hospitalizations

ARB (Class I, Level of Evidence B):

❑ ARB is recommended in symptomatic patients to reduce the risk of HF hospitalization and cardiovascular death for whom unable to tolerate an ACE-I or ARNI (patients should also receive a beta-blocker and MRA)

If-channel inhibitor :(Class IIa, Level of Evidence B) :

❑Ivabradine should be considered in symptomatic patients with LVEF <_35%, sinus rhythm on ECG and a resting heart rate >_70 b.p.m despite treatment with maximum tolerated beta-blocker, ACE-I/(or ARNI), and an MRA, to reduce the risk of HF hospitalization and cardiovascular death

If-channel inhibitor : (Class IIa, Level of Evidence C)

❑ Ivabradine should be considered in symptomatic patients with LVEF <_35%, in sinus rhythm and a resting heart rate >_70 b.p.m. who are unable to tolerate or have contraindications for a beta-blocker to reduce the risk of HF hospitalization and CV death. Patients should also receive an ACE-I (or ARNI) and MRA

Soluble guanylate cyclase receptor stimulator: (Class IIb, Level of Evidence B)

❑ Vericiguat may be considered in patients in NYHA class II-IV with worsening HF despite therapy with an ACE-I (or ARNI), a beta-blocker and MRA to reduce the risk of cardiovascular death or HF hospitalization

Hydralazine, isosorbide dinitrate : (Class IIa, Level of Evidence B)

❑ Hydralazine and isosorbide dinitrate should be considered in black patients with LVEF <_35% or with an LVEF <45% combined with a dilated left ventricle in NYHA class III-IV despite therapy with an ACE-I (or ARNI), a beta-blocker and an MRA to reduce the risk of HF hospitalization and death.1

Hydralazine, isosorbide dinitrate (Class IIb, Level of Evidence B):

❑ Hydralazine and isosorbide dinitrate may be considered in patients with symptomatic HFrEF who unable to tolerate any of an ACE-I, an ARB, or ARNI (or they are contraindicated) to reduce the risk of death

Digoxin: (ClassIIb, Level of Evidence B)

❑ Digoxin may be considered in patients with symptomatic HFrEF in sinus rhythm despite treating with an ACE-I (or ARNI), a beta- blocker and an MRA, to reduce the risk of hospitalization (both all-cause and HF hospitalizations)

The above table adopted from 2021 ESC Guideline

Diuretics

• Loop diuretics is recommended to reduce the signs and/or symptoms of congestion in patients with HFrEF.
• The effects of diuretics on morbidity and mortality have not been studied in RCTs.
• Loop diuretics and thiazide diuretics appear to reduce the risk of death and worsening HF compared with a placebo.
• Diuretics can improve exercise capacity.
• Loop diuretics and thiazides act synergistically and may be used to treat diuretic resistance.
• ARNI, MRAs, and SGLT2 inhibitors may also possess diuretic properties.
• Maintaining the euvolemia state is the aim of diuretic therapy with the lowest doses.
• Patients should be trained to self-adjust their diuretic dose based on monitoring of symptoms/signs of congestion and daily weight measurements.

Angiotensin II type I receptor blockers

• ARBs are recommended for patients who cannot tolerate ACE-I or ARNI because of serious side effects.
• CHARM-Alternative study showed candesartan reduced cardiovascular deaths and HF hospitalizations in patients who were not receiving an ACE-I due to previous intolerance.
• In the Val-HeFT trial, Valsartan, in addition to usual therapy, including ACE-I, reduced HF hospitalizations .
• ARBs have not re all-cause mortality in any trial.

Management of chronic heart failure

Intensification 2-4 months, (1-4 weeks cycles)

• In the presence of volume overload, adjusting diuretic dose and reevaluation in 1-2 weeks
• In the setting of stable euvolumic status, medications initiation, increase, switch dose and follow-up in 1-2 weeks and checking basic metabolites panel, repeating cycles until no change in clinical status and reached appropriate titration

Assessment of response to medications and cardiac remodeling

• Repeating BNP, pro BNP and basic metabolic panel
• Pepeating ECG, Echocardiography
• Refferal eligible patients to electrophysiology specialist for CRT or ICD implantation

Lack of response, instability

• Referral to advanced heart failure specialist if there are:
• Use of IV inotropes
• NYHA 3B, 4, or persistently high level of natrioretic peptide
• End organ dysfunction
• LVEF ≤ 35%
• Defibrillator shocks
• Hospitalization > 1 day
• Edema despite increase dose of diuretics
• Low blood pressure, high heart rate
• Intolerance to medications

Assessment of response to medications

• Repeating laboratory tests such as NT pro BNP, BNP, electrolytes
• Repeating ECG
• Repeating echocardiography for evaluation of structure, function
• Referral to electrophysiologic for implantation of ICD, CRT in eligible patients

Shown below is an image that summarizes the steps in the chronic management of patients with heart failure.

Management of chronic heart failure